Patents by Inventor Masakazu HOMMA
Masakazu HOMMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11787877Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.Type: GrantFiled: December 22, 2020Date of Patent: October 17, 2023Assignees: RIKEN, KYOWA KIRIN CO., LTD.Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
-
Publication number: 20230073999Abstract: An object of the present invention is to provide a polynucleotide having a modification site in a translated region with translation activity retained. The object can be achieved by a polynucleotide containing a translated region from a start codon to a stop codon, in which the translated region contains n codons, and the n is a positive integer of 2 or more, each of the n codons contains first, second and third nucleotides, and the first nucleotides in at least two codons of the n codons are sugar modified nucleotides.Type: ApplicationFiled: December 25, 2020Publication date: March 9, 2023Applicants: National University Corporation Tokai National Higher Education and Research System, Kyowa Kirin Co., Ltd.Inventors: Hiroshi ABE, Hiroto IWAI, Masakazu HOMMA, Kana ASANO, Kenji HARADA, Junichiro YAMAMOTO, Fumikazu SHINOHARA, Keiichi MOTOSAWA, Yasuaki KIMURA, Kosuke NAKAMOTO
-
Publication number: 20210107997Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.Type: ApplicationFiled: December 22, 2020Publication date: April 15, 2021Applicants: RIKEN, KYOWA KIRIN CO., LTD.Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
-
Publication number: 20210108207Abstract: The present invention provides, for example, an oligonucleotide derivative or a salt thereof comprising a circular oligonucleotide and a linear oligonucleotide, wherein the circular oligonucleotide and the linear oligonucleotide have base sequences complementary to each other, and form a complex via a hydrogen bond between the complementary base sequences, and a method for producing the same.Type: ApplicationFiled: May 1, 2018Publication date: April 15, 2021Applicant: KYOWA KIRIN CO., LTD.Inventors: Junichiro YAMAMOTO, Fumikazu SHINOHARA, Toshimasa HARUMOTO, Masakazu HOMMA, Kenji HAGIWARA
-
Patent number: 10906990Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.Type: GrantFiled: August 18, 2016Date of Patent: February 2, 2021Assignees: RIKEN, KYOWA KIRIN CO., LTD.Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
-
Patent number: 10745700Abstract: The present invention relates to a nucleic acid conjugate represented by the following formula 1: wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.Type: GrantFiled: January 30, 2017Date of Patent: August 18, 2020Assignee: KYOWA KIRIN CO., LTD.Inventors: Keiji Uehara, Yasuhiro Suzuki, Hiroto Iwai, Masakazu Homma, Yuichi Fukuda, Tatsuto Kiuchi
-
Publication number: 20190127488Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.Type: ApplicationFiled: August 18, 2016Publication date: May 2, 2019Applicants: RIKEN, KYOWA HAKKO KIRIN CO., LTD.Inventors: Kensaku SAKAMOTO, Kazumasa OHTAKE, Yoshimi YAMAGUCHI, Shigeyuki YOKOYAMA, Tatsuo YANAGISAWA, Akiko MATSUMOTO, Akifumi KATO, Yasuhisa SHIRAISHI, Kaname KIMURA, Masakazu HOMMA
-
Publication number: 20190055558Abstract: The present invention relates to a nucleic acid conjugate represented by the following formula 1: wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.Type: ApplicationFiled: January 30, 2017Publication date: February 21, 2019Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Keiji UEHARA, Yasuhiro SUZUKI, Hiroto IWAI, Masakazu HOMMA, Yuichi FUKUDA, Tatsuto KIUCHI
-
Patent number: 9701689Abstract: The present invention provides a heterocyclic compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, in which XA, R1, YA, R2, R3A, and R4A are as defined herein. The compound of formula (I) inhibits a C-C chemokine receptor type 10 (CCR10) receptor and is useful as a prophylactic and/or therapeutic agent for skin diseases.Type: GrantFiled: November 29, 2013Date of Patent: July 11, 2017Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenji Uchida, Toshimi Kanai, Masakazu Homma, Seiji Aratake, Tatsuya Ishimori
-
Publication number: 20150299214Abstract: The present invention provides a heterocyclic compound represented by the following formula (I), wherein XA represents CH and the like, R1 represents cycloalkyl optionally having substituent(s) and the like, L represents a bond and the like, YA represents —NH— and the like, R2 represents a hydrogen atom and the like, R3A represents the following formula (R3A-1) (wherein, R3 represents hydroxy and the like) and the like, and R4A represents the following formula (R4A-1) (wherein, R4 and R5 are the same or different and each represents a hydrogen atom and the like) and the like, or a pharmaceutically acceptable salt thereof, which is useful as a prophylactic and/or therapeutic agent for skin diseases and the like, and the like.Type: ApplicationFiled: November 29, 2013Publication date: October 22, 2015Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenji UCHIDA, Toshimi KANAI, Masakazu HOMMA, Seiji ARATAKE, Tatsuya ISHIMORI